These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 23628063)

  • 61. Increased incidence of EBV-related disease following paediatric stem cell transplantation with reduced-intensity conditioning.
    Cohen J; Gandhi M; Naik P; Cubitt D; Rao K; Thaker U; Davies EG; Gaspar HB; Amrolia PJ; Veys P
    Br J Haematol; 2005 Apr; 129(2):229-39. PubMed ID: 15813851
    [TBL] [Abstract][Full Text] [Related]  

  • 62. [Iatrogenic immunodeficiency-associated Epstein-Barr virus (EBV) -negative natural killer cell lymphoproliferative disorder in a patient undergoing rheumatoid arthritis therapy].
    Uchida T; Inoue M; Hua J; Tajima S; Ota Y; Hagihara M
    Rinsho Ketsueki; 2017; 58(6):624-629. PubMed ID: 28679993
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Atypical hydroa vacciniforme-like epstein-barr virus associated T/NK-cell lymphoproliferative disorder.
    Lee HY; Baek JO; Lee JR; Park SH; Jeon IS; Roh JY
    Am J Dermatopathol; 2012 Dec; 34(8):e119-24. PubMed ID: 23169419
    [TBL] [Abstract][Full Text] [Related]  

  • 64. The translation inhibitor silvestrol exhibits direct anti-tumor activity while preserving innate and adaptive immunity against EBV-driven lymphoproliferative disease.
    Patton JT; Lustberg ME; Lozanski G; Garman SL; Towns WH; Drohan CM; Lehman A; Zhang X; Bolon B; Pan L; Kinghorn AD; Grever MR; Lucas DM; Baiocchi RA
    Oncotarget; 2015 Feb; 6(5):2693-708. PubMed ID: 25393910
    [TBL] [Abstract][Full Text] [Related]  

  • 65. An unexpectedly high incidence of Epstein-Barr virus lymphoproliferative disease after CD34+ selected autologous peripheral blood stem cell transplant in neuroblastoma.
    Powell JL; Bunin NJ; Callahan C; Aplenc R; Griffin G; Grupp SA
    Bone Marrow Transplant; 2004 Mar; 33(6):651-7. PubMed ID: 14730339
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Epstein-Barr virus lytic infection contributes to lymphoproliferative disease in a SCID mouse model.
    Hong GK; Gulley ML; Feng WH; Delecluse HJ; Holley-Guthrie E; Kenney SC
    J Virol; 2005 Nov; 79(22):13993-4003. PubMed ID: 16254335
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Sequence analysis of EBV DNA isolated from mouth washings and PBMCs of healthy individuals and blood of EBV-LPD patients.
    van Kooij B; Thijsen SF; Meijer E; Niesters HG; van Esser JW; Cornelissen JJ; Verdonck LF; van Loon AM
    J Clin Virol; 2003 Sep; 28(1):85-92. PubMed ID: 12927755
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Extranodal NK/T-cell lymphoma of the nasal cavity developed in a patient with intestinal Epstein-Barr virus-positive T/NK-cell lymphoproliferative disorder.
    Furuya G; Abe H; Shinozaki-Ushiku A; Yamashita A; Ihara S; Hirata Y; Chiba A; Fujioka Y; Kurokawa M; Koike K; Fukayama M
    Pathol Res Pract; 2018 Jul; 214(7):1051-1055. PubMed ID: 29843925
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Comparison of Systemic EBV-positive T-Cell and NK-Cell Lymphoproliferative Diseases (LPD) of Childhood Based on Classification Evolution: New Classification, Old Problems.
    Xiao SY
    Am J Surg Pathol; 2021 May; 45(5):720-721. PubMed ID: 33739794
    [No Abstract]   [Full Text] [Related]  

  • 70. Lymphoproliferative disorders in autoimmune diseases in Japan: analysis of clinicopathological features and Epstein-Barr virus infection.
    Hoshida Y; Tomita Y; Zhiming D; Yamauchi A; Nakatsuka S; Kurasono Y; Arima Y; Tsudo M; Shintaku M; Aozasa K
    Int J Cancer; 2004 Jan; 108(3):443-9. PubMed ID: 14648712
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Combined immunodeficiency with life-threatening EBV-associated lymphoproliferative disorder in patients lacking functional CD27.
    Salzer E; Daschkey S; Choo S; Gombert M; Santos-Valente E; Ginzel S; Schwendinger M; Haas OA; Fritsch G; Pickl WF; Förster-Waldl E; Borkhardt A; Boztug K; Bienemann K; Seidel MG
    Haematologica; 2013 Mar; 98(3):473-8. PubMed ID: 22801960
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Early gene expression changes by Epstein-Barr virus infection of B-cells indicate CDKs and survivin as therapeutic targets for post-transplant lymphoproliferative diseases.
    Bernasconi M; Ueda S; Krukowski P; Bornhauser BC; Ladell K; Dorner M; Sigrist JA; Campidelli C; Aslandogmus R; Alessi D; Berger C; Pileri SA; Speck RF; Nadal D
    Int J Cancer; 2013 Nov; 133(10):2341-50. PubMed ID: 23640782
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Quantitative Epstein-Barr virus (EBV) serology in lung transplant recipients with primary EBV infection and/or post-transplant lymphoproliferative disease.
    Verschuuren E; van der Bij W; de Boer W; Timens W; Middeldorp J; The TH
    J Med Virol; 2003 Feb; 69(2):258-66. PubMed ID: 12683416
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Progressive transition of Epstein-Barr virus associated lymphoproliferative disease subtypes with the development of lung cancer.
    Taoka K; Nannya Y; Yamamoto G; Sakatani T; Ota S; Fukayama M; Takahashi T; Kurokawa M
    Am J Hematol; 2009 Sep; 84(9):600-3. PubMed ID: 19623671
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Epstein-Barr virus (EBV)-positive lymphoproliferations in post-transplant patients show immunoglobulin V gene mutation patterns suggesting interference of EBV with normal B cell differentiation processes.
    Bräuninger A; Spieker T; Mottok A; Baur AS; Küppers R; Hansmann ML
    Eur J Immunol; 2003 Jun; 33(6):1593-602. PubMed ID: 12778477
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Epstein-Barr Virus-Associated T- and NK-Cell Lymphoproliferative Diseases: A Review of Clinical and Pathological Features.
    Syrykh C; Péricart S; Lamaison C; Escudié F; Brousset P; Laurent C
    Cancers (Basel); 2021 Jul; 13(13):. PubMed ID: 34282778
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Characterizing EBV-associated lymphoproliferative diseases and the role of myeloid-derived suppressor cells.
    Collins PJ; Fox CP; George L; Pearce H; Ryan G; De Santo C; Mussai F; Lewis D; Long H; Shannon-Lowe C
    Blood; 2021 Jan; 137(2):203-215. PubMed ID: 33443553
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Advances in Understanding the Pathogenesis of Epstein-Barr Virus-Associated Lymphoproliferative Disorders.
    Yang X; Nishida N; Zhao X; Kanegane H
    Iran J Allergy Asthma Immunol; 2015 Oct; 14(5):462-71. PubMed ID: 26742434
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Epstein-Barr Virus-associated Lymphoproliferative Disorders in the Skin.
    Goodlad JR
    Surg Pathol Clin; 2017 Jun; 10(2):429-453. PubMed ID: 28477890
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Cellular immunotherapy with ex vivo expanded cord blood T cells in a humanized mouse model of EBV-associated lymphoproliferative disease.
    Matsuda G; Imadome K; Kawano F; Mochizuki M; Ochiai N; Morio T; Shimizu N; Fujiwara S
    Immunotherapy; 2015; 7(4):335-41. PubMed ID: 25917625
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.